zinc finger protein 133Genealiases: ZNF150 · pHZ-13 · pHZ-66
Q-omics provides the consensus-scored ZNF133 profile across patient tissues and cancer cell-line models. ZNF133 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF133 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZNF133 RNA expression shows 19,489 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where ZNF133 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF133 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF133 survival associations across molecular data types. ZNF133 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF133 RNA expression–survival associations across cancer types. High ZNF133 expression shows unfavorable associations in LIHC, KIRC, COAD and BLCA, but favorable associations in LUAD and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF133 RNA expression.
This table summarizes ZNF133 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF133. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF133 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, READ and BLCA. The HNSC box plot shows higher ZNF133 RNA expression in tumor versus normal tissue (log2 FC = +0.977, t-test p < 0.001).
This table shows molecular features associated with ZNF133 in patient tissues and cancer cell lines. In patient samples, ZNF133 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF133 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
